Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA accepts NDA for once-weekly contraceptive patch

July 4, 2012

DiscoveryBioMed receives funding to support metabolic diseases drug discovery program

July 4, 2012

New agents for hypercholesterolemia designed in Japan

July 2, 2012

Somatuline approved in Japan

July 2, 2012

Mitsubishi Tanabe drug approved for type 2 diabetes

June 29, 2012

Sanwa and Fuji submit application for hyperuricemia and gout treatment in Japan

June 29, 2012

FDA accepts Shionogi NDA for review

June 29, 2012

New notum-directed antibodies may be useful to treat osteoporosis

June 29, 2012

Studies yield encouraging VRS-317 pharmacodynamic and safety data

June 29, 2012

Janssen-Cilag applies for European approval of canagliflozin

June 28, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...